David Walker, ACR 2020 – Filgotinib for the Treatment of Rheumatoid Arthritis
We talked to David Walker (Northumbria Healthcare NHS Trust, Newcastle upon Tyne, UK) about filgotinib for the relief of pain, fatigue and improved quality of life in patients with rheumatoid arthritis (Clinical Trial Identifier: NCT02873936). The abstract ‘Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs’ (ABSTRACT NUMBER:1215) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What is filgotinib? (0:06)
- How do outcome measures recommended by regulators differ from those considered important by patients? (0:24)
- What did the FINCH-2 study show? (2:12)
- What is the importance of using patient reported outcomes in clinical trials? (3:21)
Disclosures: Speaker meetings and advisory boards for: Lilly, Gilead, Abbvie, Pfizer and Janssen.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Rheumatoid Arthritis
Kevin Winthrop, ACR 2022: Integrated safety analysis of filgotinib in moderately to severely active rheumatoid arthritis
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!